Go to main content


With an expanding R&D network,
GC Pharma brightens the future
For all humankind.

A representative photograph of developing a professional medicine.

R&D Network

In addition to striving to maximize the efficiency of its research center, GC Pharma continues to generate R&D synergy through active investment in biotechnology startups and extensive partnerships with universities, leading corporations, and research organizations worldwide. In particular, the MOGAM Institute for Biomedical Research and partner biotechnology startups in Korea and abroad with exclusive technologies have allowed GC Pharma to strengthen its position in global biopharmaceutical field.

GC Pharma’s R&D

  • RED DivisionIdentifies and analyzes candidate materials for innovative new drugs
    Handles early-stage R&D to introduce new products into the pipeline.

  • MSAT DivisionHandles later-stage R&D and improves products.

  • Medicine DivisionConducts clinical trials on products before launching.

  • Development DivisionUndertakes development projects and handles Regulatory Affairs, Business Development.

  • Partnership with leading corporations worldwide

    • R&D, clinical trials, and licensing and registration
    • Access to greater resources and expertise
    • Introduction of new candidate materials/R&D partnerships
    • Access to expansive global marketing networks
  • Biotechnology startup network
    at home and abroad

    • An extensive network with biotechnology startups in possession of prospective and exclusive technologies
    • Access to new core technologies and ideas in rapidly evolving biomedical sciences
  • Collaboration with academia

    • Access to basic/original technologies
    • Inspiration for new drug ideas
    • Strengthening the R&D pipeline
  • Collaboration with research organizations in and outside Korea

    • Research collaboration with prestigious research organizations
    • Constant access to world-class technologies

Open Innovation

GC Pharma uses its Open Innovation website to manage and coordinate collaboration
with research organizations in and outside Korea.Open Innovation


GC녹십자는 이메일 수집을 거부합니다

본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나
그 밖의 기술적 장치를 이용하여 무단으로 이메일 주소를 수집하는 행위를 거부하며,
이를 위반시 정보통신망 이용촉진 및 정보보호 등에 관한 법률에 의해 형사처벌됨을
유념하시기 바랍니다

게시일: 2003년 9월 1일